Sage Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Sage Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 45,224,000 | 81,021,000 | 99,627,000 | 99,901,000 | 172,653,000 | 70,992,000 | 148,712,000 | 121,416,000 | 206,557,000 | 162,700,000 | 199,826,000 | 206,510,000 | 178,674,000 | 294,233,000 | 422,165,000 | 514,158,000 | 899,250,000 | 1,661,082,000 | 184,270,000 | 258,228,000 | 199,444,000 | 126,705,000 | 259,181,000 | 166,185,000 | 342,295,000 | 190,943,000 | 253,123,000 | 325,830,000 | 557,555,000 | 306,235,000 | 134,916,000 | 133,450,000 | 145,460,000 | 168,517,000 | 320,078,000 | 189,003,000 | 299,680,000 | 186,753,000 | 204,877,000 | 224,234,000 | 113,162,000 | 127,766,000 | 136,727,000 | 49,127,000 |
| marketable securities | 378,630,000 | 423,397,000 | 469,527,000 | 546,892,000 | 544,360,000 | 682,192,000 | 727,340,000 | 881,200,000 | 923,028,000 | 1,109,794,000 | 1,193,813,000 | 1,307,197,000 | 1,446,567,000 | 1,448,063,000 | 1,421,004,000 | 1,397,157,000 | 1,104,767,000 | 438,467,000 | 484,267,000 | 498,294,000 | 673,313,000 | 881,688,000 | 863,069,000 | 1,070,364,000 | 1,008,956,000 | 731,833,000 | 768,278,000 | 766,603,000 | 525,958,000 | 212,613,000 | 108,535,000 | 152,478,000 | 197,104,000 | 228,962,000 | 111,192,000 | 83,292,000 | ||||||||
| prepaid expenses and other current assets | 19,893,000 | 17,749,000 | 19,630,000 | 28,743,000 | 26,588,000 | 31,825,000 | 34,705,000 | 46,321,000 | 58,850,000 | 50,826,000 | 53,017,000 | 41,455,000 | 37,206,000 | 39,841,000 | 34,343,000 | 28,846,000 | 23,083,000 | 22,821,000 | 30,347,000 | 28,862,000 | 25,479,000 | 26,700,000 | 30,413,000 | 27,021,000 | 20,281,000 | 21,919,000 | 18,511,000 | 12,958,000 | 11,575,000 | 6,227,000 | 4,892,000 | 5,192,000 | 6,480,000 | 5,100,000 | 3,418,000 | 1,812,000 | 2,926,000 | 1,738,000 | 2,604,000 | 3,274,000 | 1,367,000 | 1,056,000 | 1,063,000 | 2,416,000 |
| collaboration receivable - related party | 10,729,000 | 9,134,000 | 14,871,000 | 9,943,000 | 10,509,000 | 83,009,000 | 22,513,000 | 15,090,000 | 15,002,000 | 13,660,000 | 18,448,000 | 23,722,000 | 19,797,000 | 18,506,000 | 24,185,000 | 48,438,000 | 24,766,000 | |||||||||||||||||||||||||||
| total current assets | 454,476,000 | 531,301,000 | 604,987,000 | 686,811,000 | 755,442,000 | 869,350,000 | 933,270,000 | 1,064,027,000 | 1,203,437,000 | 1,336,980,000 | 1,465,104,000 | 1,578,884,000 | 1,682,244,000 | 1,800,643,000 | 1,901,697,000 | 1,988,599,000 | 2,051,866,000 | 2,122,370,000 | 698,884,000 | 785,384,000 | 898,236,000 | 1,035,093,000 | 1,152,663,000 | 1,263,570,000 | 1,371,532,000 | 944,695,000 | 1,039,912,000 | 1,123,769,000 | 1,095,088,000 | 525,075,000 | 248,343,000 | 291,120,000 | 349,044,000 | 402,579,000 | 434,688,000 | 274,107,000 | 302,606,000 | 188,491,000 | 207,481,000 | 227,508,000 | 114,529,000 | 128,822,000 | 137,790,000 | 51,543,000 |
| property and equipment | 778,000 | 890,000 | 1,019,000 | 1,274,000 | 1,585,000 | 1,921,000 | 2,442,000 | 2,480,000 | 2,663,000 | 2,898,000 | 2,821,000 | 2,938,000 | 2,840,000 | 3,016,000 | 2,907,000 | 3,280,000 | 4,173,000 | 6,755,000 | 7,404,000 | 8,077,000 | 8,684,000 | 9,126,000 | 9,365,000 | 8,363,000 | 6,513,000 | 5,643,000 | 5,168,000 | 4,445,000 | 4,295,000 | 4,013,000 | 1,893,000 | 1,443,000 | 1,560,000 | 1,388,000 | 1,049,000 | 959,000 | 865,000 | 286,000 | 249,000 | 285,000 | 269,000 | 163,000 | 134,000 | 69,000 |
| restricted cash | 1,450,000 | 1,332,000 | 1,332,000 | 1,332,000 | 1,332,000 | 1,332,000 | 1,332,000 | 1,269,000 | 1,269,000 | 1,269,000 | 1,269,000 | 1,269,000 | 1,269,000 | 1,269,000 | 1,269,000 | 1,269,000 | 1,716,000 | 2,367,000 | 2,367,000 | 2,367,000 | 2,367,000 | 2,367,000 | 2,367,000 | 2,367,000 | 2,367,000 | 1,919,000 | 1,269,000 | 1,269,000 | 849,000 | 849,000 | 849,000 | 564,000 | 564,000 | 564,000 | 564,000 | 39,000 | 39,000 | 39,000 | 39,000 | 39,000 | 39,000 | 39,000 | 39,000 | |
| right-of-use operating asset | 10,357,000 | 10,753,000 | 11,251,000 | 1,220,000 | 2,857,000 | 4,458,000 | 6,026,000 | 7,560,000 | 9,062,000 | 10,532,000 | 11,970,000 | 13,379,000 | 14,759,000 | 16,109,000 | 17,432,000 | 18,728,000 | 19,998,000 | 25,064,000 | 26,546,000 | 27,999,000 | 31,992,000 | 33,771,000 | 35,514,000 | |||||||||||||||||||||
| other long-term assets | 2,608,000 | 2,828,000 | 5,175,000 | 7,800,000 | 6,216,000 | 6,548,000 | 6,593,000 | 6,889,000 | 4,255,000 | 4,770,000 | 4,909,000 | 4,907,000 | 4,591,000 | 4,251,000 | 3,875,000 | 3,599,000 | 3,392,000 | 3,341,000 | 3,427,000 | 3,415,000 | 3,694,000 | 3,793,000 | 3,818,000 | 4,023,000 | 4,378,000 | |||||||||||||||||||
| total assets | 469,669,000 | 547,222,000 | 622,432,000 | 697,105,000 | 767,600,000 | 882,277,000 | 949,663,000 | 1,082,288,000 | 1,220,686,000 | 1,356,449,000 | 1,486,073,000 | 1,601,377,000 | 1,705,703,000 | 1,825,288,000 | 1,927,180,000 | 2,015,475,000 | 2,080,698,000 | 2,159,246,000 | 738,628,000 | 827,242,000 | 944,973,000 | 1,084,150,000 | 1,203,727,000 | 1,315,547,000 | 1,422,914,000 | 952,705,000 | 1,046,999,000 | 1,129,483,000 | 1,100,652,000 | 529,937,000 | 251,085,000 | 293,412,000 | 351,168,000 | 404,531,000 | 436,301,000 | 275,630,000 | 303,510,000 | 189,016,000 | 208,410,000 | 228,473,000 | 115,478,000 | 129,665,000 | 137,963,000 | 51,651,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||
| accounts payable | 5,435,000 | 12,699,000 | 7,126,000 | 8,650,000 | 6,479,000 | 10,318,000 | 11,136,000 | 9,283,000 | 12,263,000 | 18,950,000 | 7,077,000 | 5,410,000 | 7,129,000 | 10,450,000 | 4,733,000 | 2,917,000 | 3,285,000 | 3,691,000 | 4,289,000 | 2,387,000 | 7,910,000 | 15,266,000 | 5,041,000 | 12,431,000 | 13,556,000 | 34,036,000 | 5,879,000 | 8,338,000 | 8,350,000 | 9,350,000 | 13,030,000 | 6,042,000 | 8,230,000 | 12,817,000 | 5,237,000 | 5,957,000 | 4,540,000 | 5,159,000 | 3,246,000 | 5,195,000 | 2,782,000 | 2,429,000 | 2,157,000 | 1,862,000 |
| accrued expenses | 42,531,000 | 57,598,000 | 53,197,000 | 58,982,000 | 52,014,000 | 67,264,000 | 114,901,000 | 79,799,000 | 64,745,000 | 72,666,000 | 85,007,000 | 76,268,000 | 63,051,000 | 67,275,000 | 66,795,000 | 61,623,000 | 51,420,000 | 54,851,000 | 46,756,000 | 53,328,000 | 52,180,000 | 86,618,000 | 78,127,000 | 58,912,000 | 47,651,000 | 51,994,000 | 48,647,000 | 39,581,000 | 29,522,000 | 42,601,000 | 36,807,000 | 26,239,000 | 23,652,000 | 22,352,000 | 17,093,000 | 12,382,000 | 11,430,000 | 10,148,000 | 6,404,000 | 5,164,000 | 5,522,000 | 4,687,000 | 2,853,000 | 2,069,000 |
| operating lease liability, current portion | 1,812,000 | 1,318,000 | 83,000 | 1,411,000 | 3,306,000 | 5,165,000 | 6,967,000 | 7,725,000 | 7,684,000 | 7,643,000 | 7,603,000 | 7,563,000 | 7,523,000 | 7,468,000 | 7,414,000 | 7,358,000 | 7,306,000 | 8,662,000 | 8,620,000 | 8,577,000 | 10,270,000 | 10,244,000 | ||||||||||||||||||||||
| total current liabilities | 49,778,000 | 71,615,000 | 60,406,000 | 69,043,000 | 61,799,000 | 82,747,000 | 133,004,000 | 96,807,000 | 84,692,000 | 99,259,000 | 99,687,000 | 89,241,000 | 77,703,000 | 85,193,000 | 78,942,000 | 71,898,000 | 62,011,000 | 67,204,000 | 59,665,000 | 64,292,000 | 70,360,000 | 112,128,000 | 90,956,000 | 78,953,000 | 68,376,000 | 86,030,000 | 54,526,000 | 47,919,000 | 37,872,000 | 51,951,000 | 49,837,000 | 32,281,000 | 31,882,000 | 35,169,000 | 22,330,000 | 18,339,000 | 15,970,000 | 15,307,000 | 10,291,000 | 11,000,000 | 8,945,000 | 7,757,000 | 5,010,000 | 3,931,000 |
| operating lease liability, net of current portion | 10,043,000 | 10,518,000 | 10,191,000 | 1,003,000 | 2,763,000 | 4,491,000 | 6,164,000 | 7,800,000 | 9,396,000 | 10,964,000 | 12,481,000 | 13,964,000 | 15,411,000 | 19,438,000 | 21,069,000 | 22,661,000 | 24,951,000 | 26,848,000 | ||||||||||||||||||||||||||
| total liabilities | 59,821,000 | 82,133,000 | 70,597,000 | 69,043,000 | 61,799,000 | 82,747,000 | 133,004,000 | 97,912,000 | 87,557,000 | 103,850,000 | 105,951,000 | 97,141,000 | 87,201,000 | 96,257,000 | 91,526,000 | 85,963,000 | 77,422,000 | 86,912,000 | 81,047,000 | 87,327,000 | 95,767,000 | 139,495,000 | 122,656,000 | 112,672,000 | 103,380,000 | 89,734,000 | 58,494,000 | 51,720,000 | 41,376,000 | 54,462,000 | 51,033,000 | 33,108,000 | 32,722,000 | 36,014,000 | 22,564,000 | 18,421,000 | 16,010,000 | 15,321,000 | 10,306,000 | 11,022,000 | 8,968,000 | 7,780,000 | 5,044,000 | 3,971,000 |
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at march 31, 2025 and december 31, 2024; no shares issued or outstanding at march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| common stock | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | |
| treasury stock | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -400,000 | -211,000 | -211,000 | -211,000 | -211,000 | -113,000 | -17,000 | -17,000 | -17,000 | -17,000 | ||||||||||
| additional paid-in capital | 3,442,639,000 | 3,435,564,000 | 3,425,875,000 | 3,410,143,000 | 3,385,124,000 | 3,370,397,000 | 3,357,741,000 | 3,325,737,000 | 3,313,609,000 | 3,291,369,000 | 3,276,423,000 | 3,262,203,000 | 3,247,538,000 | 3,227,471,000 | 3,207,028,000 | 3,170,694,000 | 3,137,164,000 | 3,109,807,000 | 2,669,419,000 | 2,645,255,000 | 2,620,700,000 | 2,587,322,000 | 2,554,603,000 | 2,496,651,000 | 2,446,770,000 | 1,827,021,000 | 1,793,909,000 | 1,760,137,000 | 1,724,712,000 | 1,066,059,000 | 721,105,000 | 707,690,000 | 695,645,000 | 688,959,000 | 678,194,000 | 483,797,000 | 479,380,000 | 335,032,000 | 330,879,000 | 326,191,000 | 190,223,000 | 188,727,000 | 187,400,000 | |
| accumulated deficit | -3,032,539,000 | -2,970,325,000 | -2,874,547,000 | -2,780,996,000 | -2,678,142,000 | -2,569,659,000 | -2,536,953,000 | -2,335,323,000 | -2,174,998,000 | -2,028,170,000 | -1,881,024,000 | -1,743,701,000 | -1,617,441,000 | -1,495,386,000 | -1,370,674,000 | -1,240,503,000 | -1,133,258,000 | -1,037,494,000 | -2,012,389,000 | -1,906,654,000 | -1,770,307,000 | -1,643,567,000 | -1,474,914,000 | -1,294,956,000 | -1,126,735,000 | -963,329,000 | -804,941,000 | -682,023,000 | -665,045,000 | -590,447,000 | -521,025,000 | -447,306,000 | -377,105,000 | -320,327,000 | -264,426,000 | -226,630,000 | -191,883,000 | -161,340,000 | -132,778,000 | -108,743,000 | -83,716,000 | -66,845,000 | -54,484,000 | -44,792,000 |
| accumulated other comprehensive income | 142,000 | 244,000 | -81,000 | -102,000 | ||||||||||||||||||||||||||||||||||||||||
| total stockholders’ equity | 409,848,000 | 465,089,000 | 551,835,000 | 628,062,000 | 705,801,000 | 799,530,000 | 816,659,000 | 984,376,000 | 1,133,129,000 | 1,252,599,000 | 1,380,122,000 | 1,504,236,000 | 1,618,502,000 | 1,729,031,000 | 1,835,654,000 | 1,929,512,000 | 2,003,276,000 | 2,072,334,000 | 657,581,000 | 739,915,000 | 849,206,000 | 944,655,000 | 1,081,071,000 | 1,202,875,000 | 1,319,534,000 | 862,971,000 | 988,505,000 | 1,077,763,000 | 1,059,276,000 | 475,475,000 | 200,052,000 | 260,304,000 | 318,446,000 | 368,517,000 | 413,737,000 | 257,209,000 | 287,500,000 | 173,695,000 | 198,104,000 | 217,451,000 | 106,510,000 | 121,885,000 | 132,919,000 | |
| total liabilities and stockholders’ equity | 469,669,000 | 547,222,000 | 622,432,000 | 697,105,000 | 767,600,000 | 882,277,000 | 949,663,000 | 1,082,288,000 | 1,220,686,000 | 1,356,449,000 | 1,486,073,000 | 1,601,377,000 | 1,705,703,000 | 1,825,288,000 | 1,927,180,000 | 2,015,475,000 | 2,080,698,000 | 2,159,246,000 | 738,628,000 | 827,242,000 | 944,973,000 | 1,084,150,000 | 1,203,727,000 | 1,315,547,000 | 1,422,914,000 | 952,705,000 | 1,046,999,000 | 1,129,483,000 | 1,100,652,000 | 529,937,000 | 251,085,000 | 293,412,000 | 351,168,000 | 404,531,000 | 436,301,000 | 275,630,000 | 303,510,000 | 189,016,000 | 208,410,000 | 228,473,000 | 115,478,000 | |||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at december 31, 2024 and 2023; no shares issued or outstanding at december 31, 2024 and 2023 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at september 30, 2024 and december 31, 2023; no shares issued or outstanding at september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive gain | 901,000 | -2,660,000 | -306,000 | -285,000 | -236,000 | 415,000 | 946,000 | 1,709,000 | -792,000 | 1,295,000 | 1,777,000 | 1,575,000 | ||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at june 30, 2024 and december 31, 2023; no shares issued or outstanding at june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -691,000 | -787,000 | -814,000 | -3,735,000 | -5,644,000 | -5,088,000 | -10,206,000 | -14,883,000 | -13,872,000 | -11,201,000 | -106,000 | -515,000 | -257,000 | -145,000 | -185,000 | -29,000 | -15,000 | -67,000 | ||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at march 31, 2024 and december 31, 2023; no shares issued or outstanding at march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||
| other liabilities | 102,000 | 102,000 | 100,000 | 100,000 | 100,000 | 102,000 | 100,000 | 103,000 | 101,000 | 270,000 | 313,000 | 374,000 | 456,000 | 519,000 | 3,704,000 | 3,968,000 | 3,801,000 | 3,504,000 | 2,511,000 | 1,196,000 | 827,000 | 840,000 | 845,000 | 234,000 | 82,000 | 40,000 | 14,000 | 15,000 | 22,000 | 23,000 | 23,000 | |||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at december 31, 2023 and december 31, 2022; no shares issued or outstanding at december 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at september 30, 2023 and december 31, 2022; no shares issued or outstanding at september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at june 30, 2023 and december 31, 2022; no shares issued or outstanding at june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at march 31, 2023 and december 31, 2022; no shares issued or outstanding at march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at december 31, 2022 and december 31, 2021; no shares issued or outstanding at december 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at september 30, 2022 and december 31, 2021; no shares issued or outstanding at september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at june 30, 2022 and december 31, 2021; no shares issued or outstanding at june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at march 31, 2022 and december 31, 2021; no shares issued or outstanding at march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at december 31, 2021 and december 31, 2020; no shares issued or outstanding at december 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at september 30, 2021 and december 31, 2020; no shares issued or outstanding at september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at june 30, 2021 and december 31, 2020; no shares issued or outstanding at june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at march 31, 2021 and december 31, 2020; no shares issued or outstanding at march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at december 31, 2020 and december 31, 2019; no shares issued or outstanding at december 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at september 30, 2020 and december 31, 2019; no shares issued or outstanding at september 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at june 30, 2020 and december 31, 2019; no shares issued or outstanding at june 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at march 31, 2020 and december 31, 2019; no shares issued or outstanding at march 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at december 31, 2019 and december 31, 2018; no shares issued or outstanding at december 31, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||
| other current liabilities | 7,788,000 | 7,610,000 | 7,169,000 | |||||||||||||||||||||||||||||||||||||||||
| long-term lease operating liability, net of current portion | 31,360,000 | 33,309,000 | 34,528,000 | |||||||||||||||||||||||||||||||||||||||||
| other long-term liabilities | 340,000 | 410,000 | 476,000 | |||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at september 30, 2019 and december 31, 2018; no shares issued or outstanding at september 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||
| right of use operating asset | 37,224,000 | 38,124,000 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at june 30, 2019 and december 31, 2018; no shares issued or outstanding at june 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at march 31, 2019 and december 31, 2018; no shares issued or outstanding at march 31, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at december 31, 2018 and 2017; no shares issued or outstanding at december 31, 2018 and 2017 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at september 30, 2018 and december 31, 2017; no shares issued or outstanding at september 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||
| receivable from collaborator | 18,378,000 | |||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at june 30, 2018 and december 31, 2017; no shares issued or outstanding at june 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at march 31, 2018 and december 31, 2017; no shares issued or outstanding at march 31, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at december 31, 2017 and 2016; no shares issued or outstanding at december 31, 2017 and 2016 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at september 30, 2017 and december 31, 2016; no shares issued or outstanding at september 30, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at june 30, 2017 and december 31, 2016; no shares issued or outstanding at june 30, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at march 31, 2017 and december 31, 2016; no shares issued or outstanding at march 31, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||
| deferred offering costs | 200,000 | |||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at december 31, 2016 and 2015; no shares issued or outstanding at december 31, 2016 and 2015 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at september 30, 2016 and december 31, 2015, respectively; no shares issued or outstanding at september 30, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive items | -35,000 | 39,000 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share; 5,000,000 shares authorized at june 30, 2016 and december 31, 2015, respectively; no shares issued or outstanding at june 30, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 5,000,000 shares authorized at march 31, 2016 and december 31, 2015, respectively; no shares issued or outstanding at march 31, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||||||||
| deferred tax assets | 641,000 | 641,000 | 641,000 | 641,000 | ||||||||||||||||||||||||||||||||||||||||
| deferred tax liabilities | 641,000 | 641,000 | 641,000 | 641,000 | ||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 5,000,000 shares authorized at december 31, 2015 and 2014; no shares issued or outstanding at december 31, 2015 and 2014 | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 5,000,000 shares authorized at september 30, 2015 and december 31, 2014, respectively; no shares issued or outstanding at september 30, 2015 and december 31, 2014, respectively | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 5,000,000 shares authorized at june 30, 2015 and december 31, 2014, respectively; no shares issued or outstanding at june 30, 2015 and december 31, 2014, respectively | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 5,000,000 shares authorized at march 31, 2015 and december 31, 2014, respectively; no shares issued or outstanding at march 31, 2015 and december 31, 2014, respectively | ||||||||||||||||||||||||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||
| redeemable convertible preferred stock | 92,472,000 | |||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value; 5,000,000 and no shares authorized at december 31, 2014 and 2013, respectively; no shares issued or outstanding at december 31, 2014 and 2013, respectively | ||||||||||||||||||||||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 129,665,000 | 137,963,000 | ||||||||||||||||||||||||||||||||||||||||||
| other liabilities: | 34,000 | 40,000 | ||||||||||||||||||||||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -44,792,000 | |||||||||||||||||||||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ deficit | 51,651,000 | |||||||||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||
| research and development | 4,381,000 | |||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 1,807,000 | |||||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 6,188,000 | |||||||||||||||||||||||||||||||||||||||||||
| income from operations | -6,188,000 | |||||||||||||||||||||||||||||||||||||||||||
| interest income | 1,000 | |||||||||||||||||||||||||||||||||||||||||||
| other income | -5,000 | |||||||||||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -6,192,000 | |||||||||||||||||||||||||||||||||||||||||||
| accretion of redeemable convertible preferred stock to redemption value | -1,577,000 | |||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -7,769,000 | |||||||||||||||||||||||||||||||||||||||||||
| net income per share | -4,570 | |||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share attributable to common stockholders—basic and diluted | 1,700,517,000 |
We provide you with 20 years of balance sheets for Sage Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sage Therapeutics. Explore the full financial landscape of Sage Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Sage Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.